The DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.
Pharmacological characterization of a novel centrally permeable P2X7 receptor antagonist: JNJ‐47965567
Open accessAbstract
Background and Purpose: An increasing body of evidence suggests that the purinergic receptor P2X, ligand‐gated ion channel, 7 (P2X7) in the CNS may play a key role in neuropsychiatry, neurodegeneration and chronic pain. In this study, we characterized JNJ‐47965567, a centrally permeable, high‐affinity, selective P2X7 antagonist. Experimental Approach: We have used a combination of in vitro assays (calcium flux, radioligand binding, electrophysiology, IL‐1β release) in both recombinant and native systems. Target engagement of JNJ‐47965567 was demonstrated by ex vivo receptor binding autoradiography and in vivo blockade of Bz‐ATP induced IL‐1β release in the rat brain. Finally, the efficacy of JNJ‐47965567 was tested in standard models of depression, mania and neuropathic pain. Key Results: JNJ‐47965567 is potent high affinity (pK i 7.9 ± 0.07), selective human P2X7 antagonist, with no significant observed speciation. In native systems, the potency of the compound to attenuate IL‐1β release was 6.7 ± 0.07 (human blood), 7.5 ± 0.07 (human monocytes) and 7.1 ± 0.1 (rat microglia). JNJ‐47965567 exhibited target engagement in rat brain, with a brain EC 50 of 78 ± 19 ng·mL−1 (P2X7 receptor autoradiography) and functional block of Bz‐ATP induced IL‐1β release. JNJ‐47965567 (30 mg·kg−1) attenuated amphetamine‐induced hyperactivity and exhibited modest, yet significant efficacy in the rat model of neuropathic pain. No efficacy was observed in forced swim test. Conclusion and Implications: JNJ‐47965567 is centrally permeable, high affinity P2X7 antagonist that can be used to probe the role of central P2X7 in rodent models of CNS pathophysiology.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Animal research: Reporting in vivo experiments: The ARRIVE guidelines
Kilkenny, C., Browne, W., Cuthill, I. C., Emerson, M., & Altman, D. G. (2010) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2010.00872.x · Cited by 3,625
Ho Kim, S., & Mo Chung, J. (1992) · Pain · doi:10.1016/0304-3959(92)90041-9 · Cited by 3,069
Guide to receptors and channels (GRAC), 5th edition
Alexander, S., Mathie, A., & Peters, J. (2011) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2011.01649_1.x · Cited by 1,947
Guidelines for reporting experiments involving animals: the ARRIVE guidelines
McGrath, J., Drummond, G., McLachlan, E., Kilkenny, C., & Wainwright, C. (2010) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2010.00873.x · Cited by 1,592
IL-1β is an essential mediator of the antineurogenic and anhedonic effects of stress
Koo, J. W., & Duman, R. S. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0708092105 · Cited by 862
Goshen, I., Kreisel, T., Ben-Menachem-Zidon, O., Licht, T., Weidenfeld, J., Ben-Hur, T., & Yirmiya, R. (2008) · Molecular Psychiatry · doi:10.1038/sj.mp.4002055 · Cited by 762
The inflammasome: Pathways linking psychological stress, depression, and systemic illnesses
Iwata, M., Ota, K. T., & Duman, R. S. (2013) · Brain, Behavior, and Immunity · doi:10.1016/j.bbi.2012.12.008 · Cited by 580
Rao, J. S., Harry, G. J., Rapoport, S. I., & Kim, H. W. (2010) · Molecular Psychiatry · doi:10.1038/mp.2009.47 · Cited by 432
Khairova, R. A., Machado-Vieira, R., Du, J., & Manji, H. K. (2009) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145709009924 · Cited by 350
Lucae, S., Salyakina, D., Barden, N., Harvey, M., Gagné, B., Labbé, M., Binder, E. B., Uhr, M., Paez-Pereda, M., Sillaber, I., et al. (2006) · Human Molecular Genetics · doi:10.1093/hmg/ddl166 · Cited by 261
Cited by
The P2X7 Receptor Channel: Recent Developments and the Use of P2X7 Antagonists in Models of Disease
Bartlett, R., Stokes, L., & Sluyter, R. (2014) · Pharmacological Reviews · doi:10.1124/pr.113.008003 · Cited by 393
P2X7 receptor: an emerging target in central nervous system diseases
Sperlágh, B., & Illes, P. (2014) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2014.08.002 · Cited by 390
The P2X7 receptor: A main player in inflammation
Adinolfi, E., Giuliani, A. L., De Marchi, E., Pegoraro, A., Orioli, E., & Di Virgilio, F. (2018) · Biochemical Pharmacology · doi:10.1016/j.bcp.2017.12.021 · Cited by 385
Structural basis for subtype-specific inhibition of the P2X7 receptor
Karasawa, A., & Kawate, T. (2016) · eLife · doi:10.7554/elife.22153 · Cited by 303
Medicinal chemistry of adenosine, P2Y and P2X receptors
Jacobson, K. A., & Müller, C. E. (2016) · Neuropharmacology · doi:10.1016/j.neuropharm.2015.12.001 · Cited by 262
Metadata
- Authors
- Bhattacharya, A., Wang, Q., Ao, H., Shoblock, J. R., Lord, B., Aluisio, L., Fraser, I., Nepomuceno, D., Neff, R. A., Welty, N., Lovenberg, T. W., Bonaventure, P., Wickenden, A. D., & Letavic, M. A.
- Venue
- British Journal of Pharmacology
- Publisher
- Wiley
- Published
- 2013-09-17
- Volume
- 170
- Issue
- 3
- Pages
- 624-640
- ISSN
- 0007-1188 (ISSN-L)
- 1476-5381
- OpenAlex
- W1791708082
- Cited by
- 199
- References
- 14
- FWCI
- 8.95
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Pharmacological characterization of a novel centrally permeable P2X7 receptor antagonist: JNJ‐47965567. https://app.cochat.ai/papers/10.1111/bph.12314
- The paper
- Bhattacharya, A., Wang, Q., Ao, H., Shoblock, J. R., Lord, B., Aluisio, L., Fraser, I., Nepomuceno, D., Neff, R. A., Welty, N., Lovenberg, T. W., Bonaventure, P., Wickenden, A. D., & Letavic, M. A. (2013). Pharmacological characterization of a novel centrally permeable P2X7 receptor antagonist: JNJ‐47965567. British Journal of Pharmacology. https://doi.org/10.1111/bph.12314
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.